Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Merit Medical Systems has agreed to acquire View Point Medical for $140 million to expand its oncology portfolio. The deal includes $90 million paid upfront and an additional $50 million split across two payments on the first and second anniversaries of the takeover.
View Point sells tumor tissue localization devices used during biopsies and cancer resection surgeries. Its OneMark Detection Imaging System and OneMark Tissue Markers are FDA-cleared and are visualized using ultrasound. Merit expects the OneMark products to add $14 million to $16 million to sales next year.
Merit already has a tissue localization device, but it uses a different mechanism, and Merit’s Scout platform generates tissue depth data using an external probe without ultrasound.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026